adrixetinib

Adrixetinib (Q702) is an orally administered, selective small molecule inhibitor targeting the receptor tyrosine kinases Axl, Mer, and Colony-Stimulating Factor 1 Receptor (CSF1R). Developed by Qurient Co., Ltd., with originators including The Lead Discovery Center, The Max Planck Institute of Biochemistry, and Vichem Chemie, and Merck & Co. also listed as a developer, adrixetinib is being investigated for its potential in various cancers and chronic graft-versus-host disease (cGVHD). Its mechanism of action involves disrupting tumor survival pathways, reducing the activity of M2 macrophages, and enhancing anti-tumor immunity by modulating the tumor microenvironment. This multi-targeted approach aims to overcome immune evasion and drug resistance in cancer and to reduce fibrosis in conditions like cGVHD.

Other names

Axl/Mer/CSF1R triple inhibitoradrixetinib